Skip to content

Virtual Chromoendoscopy With Second Generation NBI (HQ190) vs Chromoendoscopy in Inflammatory Bowel Disease

Virtual Chromoendoscopy With Second Generation NBI (HQ190) vs Chromoendoscopy in Inflammatory Bowel Disease

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04403997
Enrollment
175
Registered
2020-05-27
Start date
2019-10-01
Completion date
2022-02-25
Last updated
2021-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chromoendoscopy

Brief summary

Study to compare the detection of neoplastic lesions between chromoendoscopy and NBI

Detailed description

Single-blind (patient) randomized study to compare detection of neoplastic lesions between chromoendoscopy and NBI. Patients with Inflammatory Bowel Disease who are to undergo chromoendoscopy according to usual clinical criteria will be included. The endoscopic procedure is similar to the one usually performed. All patients will undergo colonoscopy according to the usual procedure, with Olympus HQ190 series endoscopes, with the same bowel preparation. During intubation, the faecal remains will be thoroughly washed. Patients will be randomly assigned to one of the two techniques: Chromoendoscopy with 0.1% methylene blue or New generation NBI with Near focus. Biopsies will be taken of all those lesions detected, instead of random biopsies.

Interventions

Chromoendoscopy is an endoscopic technique used in the follow-up of inflammatory bowel disease of long evolution. Chromoendoscopy, through the application of specific dyes used directly on the intestinal mucosa, promotes the visualization of mucosal lesions.

Sponsors

Hospital Universitario La Paz
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Patients with an established diagnosis of Inflammatory Bowel Disease with indication to undergo chromoendoscopy

Exclusion criteria

* Patients who are not trained to understand the nature of the study, the procedures to be followed or are not able to sign an informed consent * Known allergy or intolerance to methylene blue * Pregnant or lactating women * Personal history of colorectal cancer * Ulcerative colitis active more than 20 cm from the anal verge * Patients with known G6PD deficiency * Severe kidney failure

Design outcomes

Primary

MeasureTime frameDescription
Lesions detectedBaselineTotal number of IBD dysplastic lesions detected by the use of NBI virtual chromoendoscopy versus conventional chromoendoscopy

Secondary

MeasureTime frameDescription
Non-dysplastic lesionsBaselineAssess the number of non-dysplastic lesions detected with both methods
Ratio of neoplastic lesions/total lesionsBaselineCompare the ratio of neoplastic lesions/total lesions between both groups
Total endoscopy timeBaselineThe total endoscopy time is counted from the introduction of the endoscope in the patient until its complete removal
Detection rate of dysplastic lesionsBaselineNumber of patients with at least one dysplastic lesion
Near Focus abilityBaselineAssess Near Focus ability to optically differentiate dysplastic from non-dysplastic lesions
Number of biopsiesBaselineNumber of biopsies taken in the different groups
Removal timeBaselineWithdrawal time is counted from the time the cecum is reached to the completion of the test, including time spent on staining, biopsy or polypectomy

Countries

Spain

Contacts

Primary ContactEduardo Martín Arranz, PhD
emarranz@salud.madrid.org+34912071350

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026